Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Bullboard Posts
Comment by LiveWireon Nov 29, 2006 10:50am
213 Views
Post# 11770544

RE: Interesting chart

RE: Interesting chartI can't recommend what you should do since I'm not a broker. Personally, I'd put in a buy order at 50% retracement of the recent breakout ($0.195). I set a stop-loss order for the entire position just below the bottom of the breakout zone ($0.135). I'd then let the stock run for a while and adjust the stop-loss order along the way later. If there's good profit, I'd consider selling half when the stock closes below the mid-channel line (currently at $0.188). I'd consider selling the other half when the stock closes below the 50 day moving average line (currently $0.134) or the bottom channel line (currently at $0.125). It's just money management and the hope that the gainers will make up for the inevitable losers.
Bullboard Posts